Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$30.80 USD
-0.31 (-1.00%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $30.78 -0.02 (-0.06%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$30.80 USD
-0.31 (-1.00%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $30.78 -0.02 (-0.06%) 7:58 PM ET
4-Sell of 5 4
A Value F Growth C Momentum C VGM
Zacks News
IART vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. IDXX: Which Stock Is the Better Value Option?
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
International expansion and the strong prospects of the CSS segment bode well for Integra (IART).
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Integra (IART) based on the prospects of its CSS segment and a stable liquidity position.
Why Is Integra (IART) Down 7.9% Since Last Earnings Report?
by Zacks Equity Research
Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Integra (IART) CSS Sales Aid, Boston Recall Hurts Growth
by Zacks Equity Research
In spite of facing foreign exchange fluctuations across its non-U.S. business, Integra (IART) is successfully broadening its international footprint.
Integra's (IART) Q2 Earnings Top Estimates, 2023 View Cut
by Zacks Equity Research
In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.
Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 24.56% and 1.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q2 Earnings on Jul 27: BSX, LH & IART
by Urmimala Biswas
Medical Device companies' second-quarter results are likely to reflect a year-over-year decline. Let's see how BSX, LH and IART fare this time.
OrthoPediatrics (KIDS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
OrthoPediatrics (KIDS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra's (IART) Codman EVD Catheter Study Data Favorable
by Zacks Equity Research
Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.
Integra (IART) Completes Enrollment in the DuraSorb IDE Study
by Zacks Equity Research
Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.
New Strong Sell Stocks for June 29th
by Zacks Equity Research
NGVT, IART and BRDG have been added to the Zacks Rank #5 (Strong Sell) List on June 29, 2023.
Here's Why You Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.
Integra (IART) Builds Advanced R&D Facility in New Jersey
by Zacks Equity Research
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Integra's (IART) Q1 Earnings Match Estimates, Margins Contract
by Zacks Equity Research
In CSS, Integra (IART) witnesses a good start to the year with double-digit growth in the CUSA product line and programmable valves as well as strong performance in instrument sales.
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Integra LifeSciences (IART) Q1 Earnings Meet Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y
by Zacks Equity Research
Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.
Integra LifeSciences (IART) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.08% and 0.05%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 158.82% and 1.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Penumbra (PEN) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Integra LifeSciences (IART) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom (DXCM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 30.77% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?